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Abstract
Introduction. Core biopsy is one of the modalities used in breast cancer diagnosis, with a 91-99% sensitivity and specificity of 96-100%. The procedure causes tumor
tissue damage to let tumor cells to enter circulation (CTC) and provoke the infiltration of inflammatory cells. Consider the side effect of core biopsy, the procedure to be
debatable/contradicting opinions. Based on this premise, this study aims to investigate Tregs and CTC count in the core biopsy procedure.
Method. A study enrolled 32 blood sample from patients of Stage III and IV breast cancer who proceed core biopsy during August to December 2016. A consecutive
sampling method employed in this study. Blood specimens taken two weeks before and after the procedure, and subjected to analyze of Tregs - (CD4, CD25, FoxP3)
and CTC count (CK19) using flow cytometry. Wilcoxon test proceeded to analyze CTC/Tregs count and Spearman correlation test proceeded to find out the correlation
of Tregs- and CTC count.
Results. A decrease of CTC after core biopsy found in median value of 50% in and p = 0.569. Median of Tregs count after core biopsy was 26.31%, with p = 0.049. We
found a small rho values (r = 0.165, r = 0.235, r = 0.046, respectively) and p > 0.0.5.
Conclusion: No correlation between Tregs - with CTC count, before or after core biopsy. The study denoted that core biopsy considered a safe method for
histopathological diagnostic purposes in breast cancer.
Keywords: breast cancer, core biopsy, Tregs, CTC

Introduction
Breast cancer is the most common malignancy in women in developed
countries and second in developing countries. The incidence of breast
cancer in Indonesia is highest compared to other malignancies. It
estimated that there are 23.140 new cases each year. The majority of
patients presented in advanced stages. The study of Ramli et al., in dr.
Cipto Mangunkusumo General Hospital (RSCM), found that those of
stage III were 43.4%, and stage IV was 14.3%. The mortality in 90% of
patients associated with metastasis to vital organs.1-3
Core biopsy is one of the diagnostic modalities in breast cancer, which
has a sensitivity of 91-99% and specificity of 96-100%. The procedure
is relatively simple, however, the side effect which is the occurrence of
CTC (circulating tumor cells) on 32% of cases, making this procedure
to become a controversy/debate between experts.4-8 Core biopsy causes
damage to tissue and tumor blood vessels. Through the damaged
vessels, the tumor cells released to circulation and known as CTC. An
acute inflammatory process follows it with vasoamine release,
degranulation of mast cells, which causes increased capillary
permeability, and infiltration of inflammatory cells to the tumor area. In
the final phase of infiltration, there is an increase in Tregs count
(regulator T lymphocytes) which releases cytokines (TGF- β, IL-10).5-10
Immunosuppression found in the microenvironment. TGF-β stimulates
COX2, which stimulates autoregulation/cell conversion of CD4+ T
lymphocytes to FoxP3+ T lymphocytes (Tregs) so that Tregs count
increased. TGF-β stimulates SOX-4 (master EMT regulator), which
causes EMT (Epithelial-Mesenchymal Transition) process. Tumor cells

transform into an invasive mesenchymal phenotype, which penetrates
vascular walls, and circulates in the blood as CTC. It can be observed
that core biopsy causes an increase in Tregs count and CTC count.5-10
In contrast, other experts believed that core biopsy is a safe diagnostic
procedure and does not cause the spreading of tumor cells through blood
circulation.11-14 The two contradicting opinions, as of the time of this
present study, the safety of core biopsy remains a debate/controversy
between experts, particularly in its reverse reaction that may induce an
increase in CTC count. This study aims to determine whether there is a
change and correlation between Tregs and CTC count before and after
core biopsy.
CTC is the gate of cancer cells into circulation so that it could result in
distant metastasis. CTC analysis from blood specimen has advantages
over tissue biopsy because it can repeatedly proceed, less invasive, early
metastasis detection, disease status, progressivity, therapeutical
response, and more accurate prognosis prediction compared to other
commonly used markers.15,16 There are five types of CTC. 1. Traditional
CTCs (intact cancer cells, viable nucleus, CK+); 2. CK- cells (stem
cells/cancer cells that had undergone EMT); 3. Apoptotic CTCs (cancer
cells that had undergone apoptosis); 4. Small CTCs (CK+ and CD45cancer-specific biomarker); and 5. CTC clusters. High CTC count (>5
cells/7.5 mL blood) correlated with a poor progression-free and overall
survival. CTC analysis uses antibody (CK19) to detect tumor cells of
epithelial cells origin.15,16
Tregs are a subpopulation of T lymphocyte that plays a role in
maintaining the innate immune system. T lymphocyte progenitor is
1
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produced in the bone marrow and undergoes maturation in the thymus,
which then differentiates into three types: 1. T-helper lymphocyte; 2.
Cytotoxic-T lymphocytes; 3. T-regulatory (Tregs) lymphocytes.
Identification and quantification of Tregs from CD4+ cells population
proceeds using flow cytometry with CD4, CD25, and FoxP3
biomarkers. Normal Tregs count in the circulation should be no more
than 0.4% of T cells population (CD4+), their presence in high
proportions in tumors is generally a poor prognostic feature. Tregs
suppresses the immune system to prevent immune reactions such as in
autoimmune disease.9,17,18 The ratio/balance of Tregs and T
helper/effector (CD8+) lymphocytes determine whether a tumor is on
progression/regression. If Tregs dominant, an immunosuppression
microenvironment/process achieved. The immune system cannot detect
tumor cells as foreign material; therefore, the tumor will progress. In
contrast, if T helper/effector (CD8+) cells dominate, tumor cells will be
recognized by the immune system and destroyed.9,10,17

CD24-FITC, CD25-PE, and Anti-FoxP3-APC antibody biomarker, and
CTC count was measured using flow cytometry with CK19 (FITC)
Santa Cruz (SC-53003) antibody biomarker. The analysis proceeded in
Clinical Pathology Laboratory RSCM/FKUI. Two weeks after the
procedure, another aspiration of blood specimen proceeded in the same
manner.
Data in numeric described in mean with standard deviation for normally
distributed ones, and median with 25 and 75 percentiles for nonnormally distributed data; categorical data presented in percentage. The
Wilcoxon– (normal distribution) and Spearman test (non-normal
distribution) were used in the study to find out the correlation between
Tregs and CTC count.
The Committee of Ethic, Faculty of Medicine, Universitas Indonesia
approved the study No. 955/UN2.F1/ETIK/2016, November 7th 2016.

Core needle biopsy causes damage to tumor tissue as well as blood
vessels. Through damaged blood vessels, tumor cells released to the
circulation (CTC). An acute inflammatory response followed, along
with the release of complement-mediated, mast cell degranulation,
vasoamine release, increased vascular permeability. During the tumor
infiltration phase, infiltration of the inflammatory cells identified,
including neutrophils, granulocytes, MSDCs, mast cells, monocytes,
and macrophages. Tregs play a role in the later phase of infiltration to
reduce the inflammatory process.5,17

Thirty-two patients met the criteria and enrolled in the study. The
subjects in the study dominated with stage III (75%), and the most
histopathology finding was invasive ductal carcinoma (81.3%).
Whereas, tumor grade of most was intermediate grade (75%). A
complete description of these characteristics presented in Table 1.

The conversion of tumor-associated macrophages from M1 to M2
phenotype increases TGF-β. Autoregulation of Tregs addition achieved
through the expression of COX2, which stimulates the conversion of
CD4+ T lymphocytes into Tregs. Thus, Tregs will found increased, and
producing an immunosuppressive microenvironment. MSDCs, Tregs,
TGF-β, and IL-10 cytokines expression will also increase gradually.
TGF-β stimulates the conversion of tumor-associated neutrophils from
N1 (anti-tumor) to N2 tumor-associated neutrophils, which secrete
CCL17 (pro-tumor), leading Tregs chemotaxis. Increased expression of
TGF-β also stimulates SOX-4 activity, which is a master EMT
regulator. EMT causes a change in property/shape of tumor cells into an
invasive mesenchymal phenotype. We carried out a study aims to
investigate Tregs and CTC count in the core biopsy procedure.
Method
The study implied a cross-sectional study in the Surgical Oncology
Division of dr. Cipto Mangunkusumo General Hospital (RSCM) and
Gatot Subroto Army Hospital (RSPAD), Jakarta, Clinical Pathology
Laboratory of RSCM from August to December 2016. The population
is all patients diagnosed as stage III and IV breast cancer managed in the
two hospitals. A consecutive sampling method was used in the study.
Those included were patients diagnosed as breast cancer stage III and IV
who underwent core biopsy while those who previously treated and
those who refuse to participate and drop out excluded.
Those who met the criteria were informed and signed the consent.
Following the enrollment, an initial 5 mL blood specimen aspirated
before biposy, a 2 mL processed for Tregs analysis, and another 3 mL
for CTC analysis. Tregs count was measured using flow cytometry with

Results

Table 1. Subjects’ Characteristics
Variable
n = 32
Gender, n (%)
Male
1 (3.1)
Female
31 (96.9)
Age (years), mean + SD
46.46 + 7.47
Stage, n (%)
III
24 (75.0)
IV
8 (25.0)
Histopathology, n (%)
IDC
26 (81.3)
DCIS
0 (0.0)
ILC
2 (6.3)
LCIS
0 (0.0)
Others
4 (12.5)
Grade, n (%)
Low
2 (6.3)
Intermediate
24 (75.0)
High
6 (18.8)
Subtype, n (%)
Luminal A
8 (25.0)
Luminal B
9 (28.1)
HER 2
4 (12.5)
TNBC
4 (12.5)
Others
7 (21.9)
Note: IDC: invasive ductal carcinoma; DCIS: Ductal
carcinoma in situ, ILC: Invasive lobular carcinoma,
LCIS: Lobular carcinoma in situ, HER2: human
epidermal growth factor receptor 2, TNBC: triplenegative breast cancer.

The Tregs count after core biopsy expressed in median analyzed using
the Wilcoxon test showed a decrease with p = 0.049, showing a
significant correlation between core biopsy and decreasing Tregs count.
While as, CTC count after core biopsy, which also expressed in median
and also analyzed using the Wilcoxon test showed a decreasing CTC
count with p = 0.569, which conveys into no significant correlation to
core biopsy (Table 2). To this finding, it assumed that core biopsy did
not lead to an increase of CTC nor Tregs count.
2
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Table 2. Correlation of core biopsy to changes in CTC and Tregs count
Variable
Before
After
p
Tregs count, median
0.20 (0.10-0.43) 0.13 (0.05-0.26)
0.049
(25th-75th percentile)
CTC count, median (25th8 (3-21)
4 (0-30)
0.569
75th percentile)
Wilcoxon correlation test

Correlation between Tregs– and CTC count
Using the Spearman analysis, we found the correlation coefficient (rho)
between Tregs– and CTC count before biopsy, after– , and delta CTC–
Tregs was very low (r = 0.165, r = 0.235, r = 0.046, respectively) with p
= 0.05 (p = 0.368, p = 0.195, and p = 0.804, respectively)(Table 3). To
this finding, it assumed that no correlation between Tregs- and CTC
count.
Table 3. Correlation of Tregs count and CTC count
Variable
r
CTC - Tregs Before
0.165
CTC - Tregs After
0.235
Delta CTC - Tregs
0.046
Spearman correlation test

p
0.368
0.195
0.804

Discussion
Of all twenty-four subjects with stage III breast cancer, twenty-two
subjects showed positive CTC value before core biopsy (91%), while in
eight subjects with stage IV, all showed positive CTC count before core
biopsy (100%). A recent study of Yap et al.,19 suggested that positive
baseline CTC count correlated with poorer outcomes. Other previous
studies also suggested that CTC may predict metastatic potential and a
higher visceral tumor burden.20 In patients with stage IV breast cancer,
baseline CTC levels may be used as an independent predictor of
progression-free and overall survival.21 In an earlier study which
compared the use of CTC count and imaging studies for prediction of
overall survival in patients with metastatic breast cancer, assessment of
CTC count found to be superior to imaging methods as CTC assay is
more reproducible one, yields useful results at an earlier time point than
imaging studies, and seems to be a more robust predictor of survival.22
The study showed a median of Tregs count before core biopsy was 0.19
out of 100 CD4+ cells, and the median of Tregs count after core biopsy
was 0.14 out of 100 CD4+ cells. We found not increased but decreased.
As data distributed not in the normal one, the Wilcoxon test carried out
to analyze and found p = 0.049, denoting a significant difference of
Tregs between before and after the core biopsy. However, this finding
in contrast to a study of Edward et al. showing an increase in Tregs count
in association to the increase of many critical inflammatory cytokines
and mediators such as S100A8, CXCL1, CXCL2, IL-1b, TNF-a, and
COX2.5 COX2 thought to stimulate the production of prostaglandin E2
(PGE2) which will in turn increase recruitment of EP-2 expressing
FoxP3+ Tregs to the tumor via the PGE2/EP2 interaction-dependent
pathway.23 However, it should be noted that these preexisting studies
were conducted in murine models.
The study findings showed that the median of CTC count before core
biopsy was eight cells per 100.000 leukocytes, and CTC count after core

biopsy was our cells per 100.000 leukocytes. We found no increase in
CTC count after core biopsy. Again, as data distribution is not a normal
one, the Wilcoxon test proceeded and showing p = 0.569. To this
finding, it assumed that the core biopsy does not affect decreasing CTC
count, in contrast to a study of Loughran CF (2011) that shows an
increase in CTC after the core biopsy.24 The difference in time of blood
specimen collection may explain the phenomenon. After the final
inflammation phase ends (approximately one week), Tregs count
expected to increase, followed by proceeding phases until EMT and
tumor escape phase occurs in approximately day 10. In this study, the
second blood specimen collection proceeded fourteen days after core
biopsy. The author expected to determine whether there is a
prolongation of the inflammatory phase and tumor infiltration, where the
tumor will continually release its cells to circulation. Another
consideration for the timing of the procedure is that during the period,
EMT and tumor escape phase is still ongoing and tumor cells that are
detected are those who had passed EMT phase that is more resistant to
immune surveillance, therefore, more clinically aggressive.5,15,20
However, other studies showed that CTC is known to have a short
survival time in the bloodstream, with an estimated range of 1 to 3
hours.25 Other than that, increased CTC count occurs greatest in the first
24 hours after core biopsy in tumor infiltration phase.15,20
Table 2 showed that the median value of CTC and Tregs are both
decreased after core biopsy. A Spearman correlation test carried out and
a low rho value found (r = 0.165, r = 0.235, r = 0.046, respectively), each
with a p-value of 0.368, p=0.195, and p=0.804, respectively. Our study
suggested that there was no significant correlation between Tregs count
and CTC count. Previous studies have suggested that Tregs count
determines CTC count. Indeed, several factors may affect CTC count
instead of CTC count. These factors are histopathological type,
aggressivity of tumor cells/tumor grade, tumor stage, and
immunological status.12,24 Furthers, in the study of Ye et al., positive
correlation between CTC count and Tregs ratio was observed in a lung
cancer.26
The core biopsy is currently established as the most frequently used
diagnostic method worldwide, mainly for malignant breast lesions.
Some authors have observed tumor cells in needle tracts and blood and
lymph vessels after core biopsy, while some others reported none in
image-guided core biopsy.27 The study demonstrated that core biopsy
does not cause an increase in CTC nor Tregs count. However, it cannot
be concluded that core biopsy is a safe diagnostic procedure because
statistically significant results were only observed in Tregs reduction but
not for CTC reduction. More extensive research with a better
quantification method of CTC and Tregs and a large sample size is
encouraged to elucidate the safety profile of core needle biopsy in breast
cancer. It suggested that core biopsy remains a safe method for
histopathological examination of breast cancer.
Conclusion
We conclude that core biopsy is considered a safe method for
histopathological examination of breast cancer.
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